Ophthotech Corporation (OPHT) and Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) Comparison side by side

Both Ophthotech Corporation (NASDAQ:OPHT) and Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) are each other’s competitor in the Biotechnology industry. Thus the contrast of their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ophthotech Corporation N/A 0.00 63.09M -1.40 0.00
Crinetics Pharmaceuticals Inc. 2.43M 247.50 27.11M -0.91 0.00

Table 1 highlights Ophthotech Corporation and Crinetics Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows the return on assets, net margins and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Ophthotech Corporation 0.00% 688.2% 97.3%
Crinetics Pharmaceuticals Inc. -1,115.64% 0% 0%

Liquidity

13 and 13 are the respective Current Ratio and a Quick Ratio of Ophthotech Corporation. Its rival Crinetics Pharmaceuticals Inc.’s Current and Quick Ratios are 31 and 31 respectively. Crinetics Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Ophthotech Corporation.

Analyst Recommendations

The Ratings and Recommendations for Ophthotech Corporation and Crinetics Pharmaceuticals Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Ophthotech Corporation 0 0 0 0.00
Crinetics Pharmaceuticals Inc. 0 0 1 3.00

Meanwhile, Crinetics Pharmaceuticals Inc.’s average target price is $40, while its potential upside is 60.00%.

Institutional & Insider Ownership

The shares of both Ophthotech Corporation and Crinetics Pharmaceuticals Inc. are owned by institutional investors at 65.6% and 98.6% respectively. Insiders owned roughly 0.2% of Ophthotech Corporation’s shares. On the other hand, insiders owned about 5.66% of Crinetics Pharmaceuticals Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Ophthotech Corporation 6.85% 23.81% -12.36% -38.82% -42.86% 30%
Crinetics Pharmaceuticals Inc. 2.61% -8.83% -31.68% -22.38% 0% -20.11%

For the past year Ophthotech Corporation has 30% stronger performance while Crinetics Pharmaceuticals Inc. has -20.11% weaker performance.

Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Its principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration (AMD). The company is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD and wet AMD. Ophthotech Corporation was founded in 2007 and is headquartered in New York, New York.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.